CVI Holdings’s Briacell Therapeutics BCTX Stock Holding History

CVI Holdings’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,139	Closed	-$1.71M	–	901
2021 Q2	$1.71M	Buy	+2,139	New	+$1.33M	0.12%	261

Other funds holding BCTX

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

STA

Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Belvedere Trading Chicago, Illinois $87.6B AUM 131.08% 1-Year Est. Return

CVI Holdings's BCTX Position: Q3 2021 in Review

CVI Holdings sold out of Briacell Therapeutics (BCTX) in Q3 2021, closing a stake of 2,139 shares — an estimated $1.71M sold.

CVI Holdings first reported a position in BCTX in Q2 2021 and held it in 1 quarter. The position peaked at $1.71M in Q2 2021. 19 funds tracked by Wall St. Rank hold BCTX as of Q3 2021.

CVI Holdings reported no remaining Briacell Therapeutics position as of Q3 2021 after selling out during the quarter.
CVI Holdings sold 2,139 Briacell Therapeutics shares in Q3 2021, an estimated $1.71M.
CVI Holdings first reported a position in Briacell Therapeutics in Q2 2021 and held it in 1 quarter.
CVI Holdings's Briacell Therapeutics position peaked at $1.71M in Q2 2021.
19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2021.

Based on CVI Holdings's 13F filing for Q3 2021, filed 15 Nov 2021.